WHO ICTRP trial
A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed…
CTIS2024-511965-13-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2024-511965-13-00 |
|---|---|
| Public title | A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer |
| Scientific title | - 20230237 |
| Primary sponsor | Amgen Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | United States;Germany |
| Conditions | Newly diagnosed localized Intermediate or High-Risk Prostate Cancer MedDRA version: 20.0Level: PTClassification code: 10060862Term: Prostate cancer Class: 100000004864;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Registration date | Sep 8, 2024 |
| Target size | 32 |
| Secondary IDs | U1111-1308-5150 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: